Therapy Areas: Respiratory
Bristol-Myers Squibb Shows Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo Plus Low-Dose Yervoy vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer
1 October 2019 - - US-based pharmaceutical company Bristol-Myers Squibb Company (NYSE: BMY) has received results from Part 1 of the Phase 3 CheckMate -227 trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC), the company said.

Opdivo plus low-dose Yervoy met the independent co-primary endpoint of overall survival, demonstrating superior benefit compared to chemotherapy in patients whose tumors expressed PD-L1 ≥1% [Hazard Ratio 0.79; 97.72% Confidence Interval : 0.65 to 0.96].

Additionally, in an exploratory analysis, results showed improved overall survival for patients treated with the combination of Opdivo plus low-dose Yervoy with PD-L1
Login
Username:

Password: